Endometrial Effects of Tibolone | Zendy

David F. Archer | Zendy; Susan L. Hendrix | Zendy; John C. Gallagher | Zendy; Janice Rymer | Zendy; Sven O. Skouby | Zendy; Alex Ferenczy | Zendy; Wil den Hollander | Zendy; V. M. Stathopoulos | Zendy; F.A. Helmond | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Endometrial Effects of Tibolone

Author(s) -

David F. Archer,

Susan L. Hendrix,

John C. Gallagher,

Janice Rymer,

Sven O. Skouby,

Alex Ferenczy,

Wil den Hollander,

V. M. Stathopoulos,

F.A. Helmond

Publication year - 2006

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2006-2207

Subject(s) - tibolone , medroxyprogesterone acetate , endometrium , medicine , endocrinology , estrogen , medroxyprogesterone

The Tibolone Histology of the Endometrium and Breast Endpoints Study is a multicenter, randomized, double-blind study designed to address the conflicting reports in the literature about the endometrial safety of tibolone (1.25 or 2.5 mg/d). Tibolone was compared with continuous combined conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) (0.625 + 2.5 mg/d).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research